Penumbra Inc (PEN) CEO Sells $1,118,880.00 in Stock

Penumbra Inc (NYSE:PEN) CEO Adam Elsesser sold 8,000 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $139.86, for a total transaction of $1,118,880.00. Following the sale, the chief executive officer now owns 1,115,838 shares of the company’s stock, valued at approximately $156,061,102.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of PEN opened at $150.45 on Friday. Penumbra Inc has a 1 year low of $110.84 and a 1 year high of $167.35. The firm has a market cap of $5.08 billion, a PE ratio of 295.00, a PEG ratio of 8.33 and a beta of 0.79.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, February 26th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. Penumbra had a net margin of 1.48% and a return on equity of 4.42%. The company had revenue of $120.80 million during the quarter, compared to the consensus estimate of $114.93 million. During the same quarter in the previous year, the company posted $0.25 earnings per share. The company’s revenue for the quarter was up 25.7% compared to the same quarter last year. Sell-side analysts expect that Penumbra Inc will post 0.83 EPS for the current year.

Several research firms have weighed in on PEN. Zacks Investment Research lowered shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. ValuEngine upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Canaccord Genuity boosted their target price on shares of Penumbra from $138.00 to $160.00 and gave the company a “buy” rating in a research note on Wednesday, January 30th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $143.43.

Several institutional investors and hedge funds have recently made changes to their positions in PEN. Wells Fargo & Company MN lifted its holdings in Penumbra by 16.3% in the third quarter. Wells Fargo & Company MN now owns 34,160 shares of the company’s stock worth $5,115,000 after purchasing an additional 4,794 shares during the period. Vanguard Group Inc. lifted its holdings in Penumbra by 2.7% in the third quarter. Vanguard Group Inc. now owns 2,646,066 shares of the company’s stock worth $396,116,000 after purchasing an additional 68,479 shares during the period. Baillie Gifford & Co. lifted its holdings in Penumbra by 35.8% in the fourth quarter. Baillie Gifford & Co. now owns 906,022 shares of the company’s stock worth $110,715,000 after purchasing an additional 239,008 shares during the period. First Trust Advisors LP lifted its holdings in Penumbra by 6.7% in the fourth quarter. First Trust Advisors LP now owns 279,456 shares of the company’s stock worth $34,150,000 after purchasing an additional 17,624 shares during the period. Finally, TD Asset Management Inc. lifted its holdings in Penumbra by 14.6% in the fourth quarter. TD Asset Management Inc. now owns 17,247 shares of the company’s stock worth $2,108,000 after purchasing an additional 2,200 shares during the period. 81.08% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://transcriptdaily.com/2019/03/15/penumbra-inc-pen-ceo-sells-1118880-00-in-stock.html.

About Penumbra

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.

Recommended Story: Understanding the different types of bonds

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.